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Remyelination promoting therapies 
in multiple sclerosis animal models: 
a systematic review and meta-
analysis
Carlijn R. Hooijmans2, Martin Hlavica1, Florian A. F. schuler3,5, Nicolas Good1, Andrin Good1, 
Lisa Baumgartner1, Gianluca Galeno1, Marc p. schneider1, tarzis Jung4, Rob de Vries2 & 
Benjamin V. Ineichen1,4
An unmet but urgent medical need is the development of myelin repair promoting therapies for Multiple 
Sclerosis (MS). Many such therapies have been pre-clinically tested using different models of toxic 
demyelination such as cuprizone, ethidium bromide, or lysolecithin and some of the therapies already 
entered clinical trials. However, keeping track on all these possible new therapies and their efficacy 
has become difficult with the increasing number of studies. In this study, we aimed at summarizing 
the current evidence on such therapies through a systematic review and at providing an estimate of 
the effects of tested interventions by a meta-analysis. We show that 88 different therapies have been 
pre-clinically tested for remyelination. 25 of them (28%) entered clinical trials. Our meta-analysis also 
identifies 16 promising therapies which did not enter a clinical trial for MS so far, among them Pigment 
epithelium-derived factor, Plateled derived growth factor, and Tocopherol derivate TFA-12.We also 
show that failure in bench to bedside translation from certain therapies may in part be attributable to 
poor study quality. By addressing these problems, clinical translation might be smoother and possibly 
animal numbers could be reduced.
Multiple Sclerosis (MS) is a chronic demyelinating disease1. With the only exception of Ocrelizumab2, which 
has a modest impact on disease progression, none of the 16 FDA approved MS therapies are able to stop or at 
least to decelerate the progressively increasing disability of affected patients3. One well-acknowledged approach 
to prevent disease progression is via a boost of myelin repair. Remyelination not only restores efficient electric 
conduction along axons but, because the myelin sheaths have trophic functions for the axons4, also reduces neu-
rodegeneration, which closely correlates with clinical disability5.
The intense search for strategies to enhance myelin regeneration to hinder further neurodegeneration and 
to increase clinical function of patients, is as well reflected by the large number of pre-clinical studies assessing 
potential remyelinating strategies. Commonly used experimental systems to study potential remyelinating ther-
apies include neuro-inflammatory animal models such as experimental autoimmune encephalomyelitis (EAE)6 
or virus-induced demyelination/inflammation7 as well as toxin-induced demyelination models with cuprizone8, 
lysolecithin, ethidium bromide, and complement/anti-galactocerebroside antibodies9 being the most commonly 
used agents of the latter group10. All of these models have strengths and limitations; whereas neuro-inflammatory 
models reproduce well the disseminated and inflammatory features of MS, toxin-induced demyelination models 
are more suited to dissect specific mechanisms of myelin decline and regeneration with a clear temporal separa-
tion of these processes and without concomitant inflammation10,11.
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Cuprizone is a systemic copper-chelating agent. Upon feeding, it leads to demyelination of distinct brain 
regions, among them the corpus callosum. Cuprizone has a highly reproducible timeline of de- and remyeli-
nation and enables long-term demyelination when fed for a prolonged time window. The exact mechanism of 
cuprizone-induced demyelination is unknown10,12. Compared to Cuprizone, lysolecithin has the disadvantage 
of needing an invasive injection to a pre-defined CNS-position. Nevertheless, it is also highly predictive under 
temporal aspects. Moreover, any CNS area can be targeted selectively with this detergent13. Ethidium bromide 
leads to much larger areas of demyelination and degrades all nucleated cells within the injection area (including 
astrocytes and microglia cells)9. The local injection of Anti-galactocerebroside antibodies/complement is rarely 
used as toxic demyelination model. The time to complete remyelination is shorter in this model but involves a 
greater demyelinating area than lysolecithin10.
Many putative therapies have been identified using these toxic demyelination models, from which some 
already entered clinical trials. We aimed at summarizing all the already pre-clinically tested putative remyelinat-
ing therapies via a systematic review and meta-analysis in order to assess which remyelinating therapies can be 
promising and could be tested in clinical trials. We also investigate the efficacy of the therapies in these  experi-
mental animal models that have already entered clinical trials. We focused our analysis on the four in vivo toxic 
demyelination models cuprizone, lysolecithin, ethidium bromide, and complement/anti-galactocerebroside anti-
bodies. These models might be more suited to assess potential therapies aiming at halting disease progression of 
progressive MS in contrast to neuro-inflammatory models, in which potential immune-modulatory effects of 
therapies could confound efficacy11. The results of our review should provide a framework for future clinical trials 
investigating putative remyelinating interventions for MS, in particular during the chronic phase of the disease 
when remyelination failure determines disability progression.
Results
study characteristics. Study selection process. Figure 1 depicts the Quorum flow chart of the study selec-
tion process14. Using 4 different search strings for anti-galactocerebroside antibodies, cuprizone, ethidium bro-
mide, and lysolecithin, respectively (see Supplementary Information), a total of 6545 publications were retrieved 
from EMBASE, go3R, Medline, Pubmed, Scopus, and Web of Sciences. After initial screening of titles and 
abstracts, 263 publications were included for full-text search. Out of these, 103 studies met our inclusion criteria 
(see supplementary reference list). The remainder were excluded according to the criteria listed in Fig. 1.
Figure 1. Quorum chart of the study selection process14. Duplicate references are references that are mentioned 
in multiple medical databases (e.g. same references in Embase and Pubmed) or studies published in duplicate 
(e.g. same study in multiple journals).
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Publication over time. The first reports using models of toxic demyelination in vivo were published in the sev-
enties. Lysolecithin was the first model being published in 197115, followed by cuprizone in 197216, ethidium bro-
mide in early 197917, and anti-galactocerebroside antibodies in mid 197918. The first reports using these models 
to assess a therapy for its remyelinating potential in vivo and meeting our inclusion criteria, however, was only in 
199719. Thus, all studies included in the meta-analysis were published between 1997 and 2016 (Fig. 2).
Description of the included studies. The characteristics of the 103 included studies are shown in Supplementary 
Table 1. A total of 88 different therapies were tested in the included studies. 59 studies used cuprizone (58%), 30 
studies used lysolecithin (29%), 14 studies used ethidium bromide (13%), and none of the included studies used 
anti-galactocerebroside antibodies as demyelination model. Only two different animal species have been used in 
the included studies: mice (72 studies, 70%) and rats (31 studies, 30%). Most studies used male animals (47, 45%), 
whereas females were less commonly used (28, 27%); 25 studies (24%) did not report which sex they used, and 
3 studies (3%) combined female and male animals within the same experimental groups. Most of the studies 
used remyelination as an outcome measure (95, 93%), 54 of them (52%) investigated remyelination as the single 
outcome without using oligodendrocyte or OPC counts as outcome. 51 used oligodendrocyte cell counts (50%), 
and 33 used oligodendrocyte precursor cells (OPC) counts as outcome (32%). Nine studies (9%) did not directly 
assess remyelination but assessed oligodendrocyte or OPC counts only. Seventeen studies (17%) assessed all three 
outcome measures remyelination, oligodendrocyte, and OPC count (Fig. 3).
Study quality and risk of bias. Figure 4 depicts the risk of bias assessment for the 103 included studies. For many 
items of the adapted SYRCLE risk of bias tool20, poor reporting regarding experimental details led overall to an 
unclear risk of bias. Assessment of selection bias showed that none of the included studies described whether or 
not they blinded the allocation of the animals to the experimental or groups or described the methods used for 
allocation sequence generation. Although only 5% of the papers reported any measure used to randomise the 
experiment, fortunately 68% of publications reported similar experimental groups at baseline. Regarding the risk 
Figure 2. Histogram depicting the number of included studies per year.
Figure 3. Venn diagram illustrating how many of the 103 studies assessed one or more of the outcomes 
remyelination, oligodendrocyte precursor (OPC) count, and oligodendrocyte count.
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of performance bias, none of the publications reported whether the animals were randomly housed across cages 
and rooms during the experiment. 38% of the publications reported that staff was blinded during the experi-
ments. Concerning the risk of detection bias, none of the publications reported on random outcome assessment 
whereas in 13% of the studies, the outcome assessor had been blinded for animal allocation. Measures to reduce 
attrition bias were reported in 10% of publications. There was a high risk of attrition bias in 3%. In 87%, the risk of 
attrition bias was unclear as a consequence of poor reporting of the number of experimental animals used in both 
methods and result sections of the papers. Sample sizes appeared small in most of the included studies, although 
only 2% of the included studies reported a a prior sample size calculation. The median number of animals in the 
treatment or control group was between 5 and 5.5 (Table 1).
Because poor reporting in preclinical studies is a known problem and therefore many items of the risk of bias 
tool are scored as unclear risk of bias, we additionally scored two reporting items. These items were also scored in 
a similar study in EAE21 and in focal cerebral ischemia (FCI)22: Five percent of studies reported randomization at 
any level (For comparison - EAE: 9%, FCI: 36%). Blinding of the experiment at any level was reported in 38% of 
studies (For comparison - EAE: 16%, FCI: 29%).
Finally, 2 studies (1.8%) reported a prior sample size calculation (EAE: <1%, FCI: 3%) whereas 2 studies 
(1.8%) reported no prior sample size calculation. The remaining publications did not mention whether a sample 
size calculation has been performed. Compliance with animal welfare regulations or an approved animal license 
were reported in 58% of cases (For comparison - EAE: 32%, FCI: 57%). A statement whether a conflict of interest 
was present was reported in 38% of studies (For comparison - EAE: 6%, FCI: 23%).
Meta-analysis. Remyelination as outcome. In the studies measuring remyelination, different methods were 
used in the 110 comparisons: most investigators used electron microscopy as outcome (32 experiments, 29%), 
followed by myelin basic protein (MBP) immunohistofluorescence/-chemistry (26 experiments, 24%), Luxol Fast 
Blue (LFB) staining (17 experiments, 15%), and Toluidine blue staining on semithin sections (11 experiments, 
10%). In contrast, Black Gold staining (8 experiments, 7%), Hematoxylin and Eosin staining (5 experiments, 5%), 
PLP immunohistofluorescence (4 experiments, 4%), Eriochrome staining (3 experiments, 3%), MOG immuno-
histochemistry (2 experiments, 2%), MRI lesion load (1 experiment, 1%), and MRI magnetization transfer (1 
experiment, 1%) were less commonly used.
Figure 4. Risk of bias assessment of the included studies. The first 8 items assess study quality by reporting 
“yes” indicating low risk of bias, “no” high risk of bias, and “unclear” as not reported20. The remaining 5 items 
score a “yes” if reported and a “no” if not reported.
Outcome
Median/mean number 
(±SD) of animals in 
treatment group
Median/mean number 
(±SD) of animals in 
control group Range
Remyelination 5.5/6.7 (±3.7) 5/6.1 (±3.7) 2–21
Oligodendrocyte 
cell counts 5/6.5 (±3.7) 5/6.1 (±3.5) 3–18
OPC counts 5/6.5 (±3.8) 5/6.4 (±3.7) 3–21
Table 1. Sample sizes of the included studies, Abbreviations: SD, standard deviation; OPC, oligodendrocyte 
precursor cells.
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Pooling the individual effect sizes of all therapies in our meta analyses showed that the therapies described in 
literature enhance remyelination (Standardized mean difference (SMD): 1.61, 95% CI: [1.26, 1.97], Table 2). The 
overall heterogeneity23 between the studies, however, was high (I2 = 85%), reflecting the anticipated differences 
between interventions, models used and study design.
In order to obtain a more detailed overview of the efficacy of the various therapies included in this review, 
we also analysed the effect of the seventy-eight different therapeutic approaches in 110 different comparisons for 
their remyelination potential as measured by different morphometric approaches (i.e. the quantification of thinly 
myelinated axons in electron microscopy or by similar methods) separately. Nineteen therapeutic approaches 
significantly enhanced remyelination (Anti-Lingo-1-antibody, Ebselen, Electro acupuncture, Electromagnetic 
field stimulation, Epimedium flavonoids, Glatiramer acetate, Indazol chloride, N6-cyclohexyladenosine, 
Neurotrophin 3, Ninjińyoeito, Plateled-derived growth factor, Progesterone, Quetiapine, Sildenafil, SiRNA 
against Nogo-receptor, Testosterone, Tocopherol derivate TFA12, Triiodothyronine, and Vitamin E) and four 
therapies dampened the remyelination after experimental demyelination (Dizocilipine, Simvastatin, Trapidil, and 
Valproic acid) (Figs 5 and 6). For the remaining 55 therapeutic approaches, no statistically significant results were 
found. In many cases, only one or a few studies were available per therapeutic approach.
Further subgroup analyses for timing of the intervention (e.g. prophylactical or therapeutical administration) 
or type of model used revealed no differences. Due to the small number of comparisons in the subgroups, these 
results must be interpreted with caution.
Oligodendrocyte precursor cell (OPC) count as outcome. In the studies visualizing OPCs, different methods were 
used in the 34 different comparisons: NG2 was the most commonly used marker for OPCs (19 experiments, 
56%), followed by PDGFRα (13 experiments, 38%). In contrast, Nkx2.2 (2 experiments, 6%) was less commonly 
used.
Pooling the individual effect sizes (SMDs) of all 34 experiments investigating the effect of various therapies on 
OPC counts did not show a significant effect (SMD: 0.87, 95% CI: [−0.08, 1.83], Table 3). The overall heteroge-
neity was very high (I2 = 92%).
Thirty-one different therapeutic approaches in 34 different comparisons were tested for their impact on 
OPC counts as measured by cell counts of different immune-staining methods (i.e. NG2, PDGFRα, or Nkx2.2). 
The effectsizes (SMDs) and 95% CIs indicated that 7 therapeutic approaches significantly increased the OPC 
count (Electro acupuncture, Iloprost, Pigment epithelium-derived factor (PEDF), Platelet-derived growth factor 
(PDGF), Testosterone, Triiodothyronine, and Valproic acid) and 3 therapies significantly decreased the OPC 
count after experimental demyelination (Apotransferrin, Epimedium flavonoids, and Lactacystin) (Fig. 7). For 
the remaining 21 therapeutic approaches, no statistically significant effects were found. In many cases, only one or 
a few studies were available per therapeutic approach. No statistically significant differences between subgroups 
could be identified for type of model used or timing of the intervention (the subgroup of prophylactic adminis-
tration was too small).
Oligodendrocytes as outcome. In the studies visualizing oligodendrocytes, different methods were used in the 
55 comparisons: APC (CC1) was the most commonly used marker for oligodendrocytes (20 experiments, 36%), 
followed by GST-pi (11 experiments, 20%), and Nogo-A (9 experiments, 16%). In contrast, CA2 (5 experiments, 
9%), CNP (4 experiments, 7%), O4 (3 experiments, 5%), and Olig2/APC (CC1) double staining (3 experiments, 
5%), were used less commonly.
Subgroup Comparisons
Effect estimate 
[95% CI] I2
Overall 110 1.61 [1.26, 1.97] 85%
MS model
Cuprizone 66 1.61 [1.16, 2.07] 83%
Ethidium bromide 16 1.67 [0.68, 2.65] 87%
Lysolecithin 28 1.60 [0.90, 2.30] 86%
Method
Electron microscopy 32 1.73 [1.05, 2.40] 87%
MBP immuno-staining 26 2.16 [1.44, 2.87] 82%
Luxol fast blue 17 1.85 [0.97, 2.73] 79%
H&E lesion area 5 5.17 [2.83, 7.51] 92%
MOG immune-staining 2 3.29 [0.23, 6.35] 85%
Therapeutic regimen
therapeutically 102 1.67 [1.30, 2.04] 84%
Table 2. subgroup analysis of the included studies for outcome remyelination. The effect estimate was displayed 
by the standardized mean difference (SMD) and 95% confidence intervals (CIs). No significant differences 
were found in the subgroup analyses. Abbreviations: MBP, myelin basic protein; MOG, myelin oligodendrocyte 
glycoprotein.
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Meta analyses showed that the assessed therapies can increase oligodendrocyte cell counts (SMD: 2.09, 95% 
CI: [1. 52, 2.66], Table 4). The overall heterogeneity, however, was high (I2 = 87%), reflecting the anticipated dif-
ferences between interventions, models used and study design.
Subsequently, we investigated the effect of each therapy separately on oligodendrocytes cell counts. Forty-three 
different therapies in 55 different comparisons were tested for their impact on oligodendrocyte cell counts as 
measured by cell counts of different immune-staining methods (e.g. APC, CA2, Nogo-A, or others). The SMDs 
and 95% CIs indicated that 12 therapies significantly increased the oligodendrocyte cell counts (Apotransferrin, 
Benztropine, Electro acupuncture, Estrogen receptor agonist G1, Olesoxime, Pigment epithelium derived factor, 
Progesterone, Quetiapine, Sonic hedgehog, Testosterone, Tocopherol derivate TFA-12, and Triiodothyronine) 
and one therapy significantly decreased the oligodendrocyte cell counts after experimental demyelination (val-
proic acid, SMD −11.77, 95%-CI [−18.04, −5.49], 1 comparison) (Fig. 8). For the remaining 30 therapeutic 
approaches, no statistically significant results were found.
The number of independent comparisons per therapeutic approach were very low and varied between 1 and 
4. No differences between subgroups were found for timing of the intervention. However, subgroup analyses for 
type of model used revealed that the type of model used to measure oligodendrocytes cell counts partly explains 
the observed heterogeneity between the studies. use of the LPC model significantly yielded more oligodendrocyte 
cell counts compared to the cuprizone model (p < 0.001).
publication bias. Both visual inspection of the funnel plot and Egger regression did not suggest the presence 
of publication bias for remyelination, OPCs, and oligodendrocyte data. The funnel plots show no significant 
asymmetry, and no trimming could be performed (Fig. 9). Egger regression also showed no evidence for small 
study effects (remyelination p = 0.153, OPCs p = 0.063, oligodendrocytes p = 0.99).
synopsis of the results. Table 5 compares the therapies with a significant result in the meta-analysis and 
their impact on the outcomes remyelination, OPC count, and oligodendrocyte count and indicates whether a 
therapy has already entered a clinical trial. Most of the therapies that entered a clinical trial showed a beneficial 
Figure 5. Forest plot of the included studies for the outcome remyelination (part 1). The diamond indicates 
the global estimate and its 95% confidence interval (CI). The numbers listed after a certain intervention are: the 
exact effect size with its 95% CI, the number of included studies for a certain intervention (ns), the total number 
of treated animals (nt) or control animals (nc). The gray bar indicates the 95% CI of the overall effect size. 
References are given in the Supplementary Information. *The growth factor cocktail contained Platelet derived 
growth factor-AA, neurotrophin-3, basic fibroblast growth factor, and insulin-like growth factor-1.
www.nature.com/scientificreports/
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effect in at least one of the three outcomes, except for Simvastatin (2 comparisons for remyelination, 1 for each 
OPC and oligodendrocyte counts). Simvastatin significantly decreased remyelination in experimental animal 
models and showed no effect on either OPC and oligodendrocyte numbers, but is already being tested in a phase 
4 clinical trial for progressive MS.
Sixteen therapeutic strategies that have not yet been tested in clinical trials seem promising and scored at 
least one significant increase in one of our 3 remyelination outcomes and no negative effects: Apotransferrin, 
Benztropine, Epimedium flavonoids (an extract of epimedium sagittatum), Estrogen receptor agonist G1, Iloprost 
(prostaglandin I2), Indazol chloride (an Estrogen receptor agonist), N6-cyclohexyladenosine (an Adenosine 
A1 receptor agonist), Neurotrophin 3, Ninjin’yoeito (an extract from different medicinal herbs), Olesoxime (a 
cholesterol-like compound), Pigment epithelium-derived factor (PEDF), Plateled derived growth factor (PDGF), 
Sildenafil (a phosphodiesterase inhibitor), siRNA against Nogo-receptor, Sonic hedgehog, and Tocopherol deri-
vate TFA-12 (a Vitamin E derivate). For most therapies, however, only one comparison was available for our 
meta-analysis. Three of these possible therapies seem very promising as they scored a significant increase in 2 of 
Figure 6. Forest plot of the included studies for the outcome remyelination (part 2). The diamond indicates 
the global estimate and its 95% confidence interval (CI). The numbers listed after a certain intervention are: the 
exact effect size with its 95% CI, the number of included studies for a certain intervention (ns), the total number 
of treated animals (nt) or control animals (nc). The gray bar indicates the 95% CI of the overall effect size. 
References are given in the Supplementary Information.
Subgroup Comparisons Effect estimate [95% CI] I2
Overall 34 0.87 [−0.08, 1.83] 92%
Therapeutic regimen
therapeutically 29 1.31 [0.25, 2.37] 93%
Method
PDGFRα 13 2.50 [0.51, 4.49] 94%
Table 3. subgroup analysis of the included studies for outcome oligodendrocyte precursor cell counts. The 
effect estimate was displayed by the standardized mean difference (SMD) and 95% confidence intervals (CIs). 
No significant differences were found in the subgroup analyses.
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the 3 outcome measures assessed and no negative effects in the remaining outcome: PDGF, PEDF, and Tocopherol 
derivate TFA-12 (each with one comparison). In Fig. 10, the meta-analysis outcomes remyelination, oligoden-
drocyte cell/OPC cell counts are plotted against each other for each therapy, which has been tested in at least two 
outcomes. The scatter plots demonstrate a good correlation (Pearson’s r = 0.51, two-tailed p = 0.02) between the 
outcome remyelination and oligodendrocytes.
Figure 7. Forest plot of the included studies for outcome oligodendrocyte precursor cell (OPC) count. The 
diamond indicates the global estimate and its 95% confidence interval (CI). The gray bar indicates the 95% CI 
of the overall effect size. The numbers listed after a certain intervention are: the exact effect size with its 95% 
CI, the number of included studies for a certain intervention (ns), the total number of treated animals (nt) or 
control animals (nc). References are given in the Supplementary Information.
Subgroup Comparisons Effect estimate [95% CI] I2
Overall 55 2.09 [1.52, 2.66] 87%
Therapeutic regimen
therapeutically 49 2.10 [1.48, 2.71] 86%
Method
APC* 20 2.43 [1.48, 3.38] 88%
GST-pi 11 2.14 [0.91, 3.37] 83%
Nogo-A* 9 0.12 [−1.16, 1.36] 72%
CA2 5 3.64 [1.71, 5. 57] 83%
O4 3 4.86 [2.31, 7.41] 96%
Olig2/APC 3 2.51 [0.13, 4.89] 48%
MS model
Cuprizone*** 42 1.77 [1.12, 2.41] 86%
Lysolecithin*** 10 3.71 [2.27, 5.15] 91%
Table 4. Subgroup analysis of the included studies for outcome oligodendrocytes cell counts. The effect 
estimate was displayed by the standardized mean difference (SMD) and 95% confidence intervals (CIs). 
*Significant subgroup analysis between Nogo-A and APC (adjusted p = 0.049), and Cuprizone and Lysolecithin.
www.nature.com/scientificreports/
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Clinical trials. Table 6 summarizes the therapies that were tested in toxic demyelination models that have 
entered clinical trials (phase 1 to 4). Out of 88 interventions identified by our systematic review, 25 (28%) have 
already entered clinical trials. Five of these reached FDA-approval (Fingolimod, Fumaric acid ester, Glatiramer 
acetate, Methotrexate, Methylprednisolone).
Discussion
Finding remyelinating therapies for MS is an urgent and unmet medical need because no such therapies are cur-
rently available. Regeneration of myelin sheaths would re-enable efficient electrical conduction along axons and 
furthermore protect axons from neurodegeneration4. Many such potential approaches have been pre-clinically 
tested so far. In order to obtain an overview of possible promising remyelinating therapies, we systematically 
reviewed pre-clinical studies assessing therapies aiming at improving myelin repair. Our review provides evidence 
that pre-clinically tested therapies significantly increase remyelination and oligodendrocyte cell counts overall. In 
addition, we show that there are numerous other therapies that seem promising based on our meta-analysis that 
are not yet tested in clinical trials.
Overall meta-analysis of the outcome remyelination showed that 19 out of 78 therapies (24%) enhanced remy-
elination. Four therapies dampened the remyelination, among them valproic acid and Simvastatin (1 and 2 com-
parisons included, respectively). Nevertheless, Simvastatin was, based on experimental studies conducted in EAE, 
already tested in several clinical trials due to its presumptive immunomodulatory and neuroprotective effects24. It 
appeared to be successful in a recent phase 2 trial in secondary progressive MS patients25,26. It failed, however, in 
a phase 4 trial in relapsing remitting MS27. This demonstrates that neuroprotective properties rather than immu-
nomodulation might be its primary mode of action24. Besides that, Simvastatin, a blood-brain barrier permeable 
statin, is an inhibitor of cholesterol synthesis. It has been shown in vitro and in vivo to dampen the maturation/
differentiation of OPCs to myelinating oligodendrocytes via inhibition of the Rho kinase (ROCK) downstream 
pathway28,29. Another statin, Lovastatin has also been shown to affect OPC maturation in vitro, namely by inhi-
bition of the cholesterol synthesis thereby affecting the proteolipid protein (PLP) transport towards the myelin 
sheaths30. It seems therefore plausible that one should carefully monitor the effect of statins in the therapy of MS 
and other demyelinating diseases29,30.
Figure 8. Forest plot of the included studies for outcome oligodendrocyte count. The diamond indicates the 
global estimate and its 95% confidence interval (CI). The gray bar indicates the 95% CI of the overall effect 
size. The numbers listed after a certain intervention are: the exact effect size with its 95% CI, the number of 
included studies for a certain intervention (ns), the total number of treated animals (nt) or control animals (nc). 
References are given in the Supplementary Information.
www.nature.com/scientificreports/
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Meta-analysis of the outcome oligodendrocyte cell counts demonstrated that 12 out of 43 (28%) therapies 
increased oligodendrocyte cell counts. Valproic acid was the only intervention significantly decreasing the oli-
godendrocyte cell count. Together with its increase in the OPC count, oligodendrocyte differentiation blocking 
properties have been revealed (via inhibition of histone deacetylases)31. Intriguingly, this antiepileptic drug has 
repeatedly shown beneficial effects in EAE and optic neuritis animal models32,33. Data from a retrospective cohort 
study in MS patients were negative, however34. This emphasizes that a good pre-clinical scientific fundament for 
a presumptive remyelinating therapy using also toxic demyelination models can help to decide whether a therapy 
should be tested in a clinical trial.
Meta-analysis of the outcome OPC count revealed that 7 out of 31 therapies (23%) increased the OPC count 
whereas 3 decreased it (Apotransferrin, Epimedium flavonoids, Lactacystin). Overall analysis of the outcome 
OPC count revealed no statistically significant effect. Assessing OPC count as the single outcome for a presump-
tive remyelinating therapy is not ideal because increased OPC counts can be at the cost of decreased oligoden-
drocyte counts (cell differentiation block), as shown by the absence of correlation between OPC counts and 
remyelination in our analysis. This fits also to the extensive evidence showing that OPCs can be present at the 
border or even inside experimental demyelinated lesions35,36 and chronic demyelinated MS lesions37–42 without 
differentiating to oligodendrocytes. Proof of this OPC differentiation block with resulting remyelination failure 
has led to a paradigm shift in the remyelination field, focusing more on ways to foster OPC differentiation than 
OPC proliferation43,44 (reviewed in45).
Interestingly, the meta-analysis outcomes remyelination and oligodendrocyte cell counts showed a significant 
positive correlation when plotted against each other. This possibly shows that remyelination alone might be a 
sufficient outcome measure for future pre-clinical trials.
Clinical relevance and recommendations. Out of 88 included therapies, at least 25 (28%) entered one 
or more clinical trials and/or reached clinical approval. Our meta-analysis resulted in another 16 therapeutic 
strategies that have not yet been tested in clinical trials but seem promising (i.e. Apotransferrin, Benztropine, 
Epimedium flavonoids (extract of epimedium sagittatum), Estrogen receptor agonist G1, Iloprost (prostaglandin 
I2), Indazol chloride (an Estrogen receptor agonist), N6-cyclohexyladenosine (Adenosine A1 receptor agonist), 
Neurotrophin 3, Ninjin’yoeito (extract from different medicinal herbs), Olesoxime (cholesterol-like compound), 
Pigment epithelium-derived factor (PEDF), Plateled derived growth factor (PDGF), Sildenafil (phosphodiester-
ase inhibitor), siRNA against Nogo-receptor, Sonic hedgehog, and Tocopherol derivate TFA-12 (Vitamin E deri-
vate)). Our results suggest that treatment with PDGF, PEDF, or Tocopherol derivate TFA-12 are particularly 
interesting for further investigations because treatment with these drugs showed favourable outcomes in two out 
of three of our remyelinating outcomes.
Figure 9. Evaluation of publication bias. Panel A, B and C represent the funnel plots for the outcomes 
remyelination, oligodendrocyte precursor cells (OPC) and oligodendrocyte count. The line represents the SMD 
of the summary effect, the grey bands represent global 95% confidence intervals.
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Following this, it would also be very useful to investigate whether the results of the currently conducted clini-
cal trials show comparable results with our review results.
Correlation with therapies which have entered clinical trials. For some of the clinical trials the 
results are already published. Whereas some pre-clinically assessed therapies therapies already reached mar-
ket approval, the clinical translation is sometimes hampered. A good example are anti-Lingo-1 antibodies. 
These antibodies effectively and consistently enhanced remyelination in different MS animal models. However, 
the failure of anti-Lingo-1-antibodies in a phase 2 trial to meet the primary outcome in relapsing/progressive 
MS patients, a multicomponent analysis evaluating motor and cognitive function as well as disability, were 
sobering (http://media.biogen.com/press-release/investor-relations/biogen-reports-top-line-results-phase-
2-study-opicinumab-anti-lingo). In our meta-analysis, anti-Lingo-1-antibodies did only show a significant 
increase in remyelination but not in oligodendrocyte cell counts. Cyclosporin is another therapy that showed ben-
eficial effects in the ethidium bromide model46 (although not in our meta-analysis) but failed in clinical trials47. 
Of course, some of these therapies made it into clinical trials not because of their results in toxic demyelination 
models assessed here, but because of their results in neuro-inflammatory animal models such as EAE48.
Limitations. An important limitation of this review, as in many other systematic reviews of animal stud-
ies49 is that many of the essential methodological details of animal studies included in our review were poorly 
reported. This seriously hampers reliable risk of bias assessment because in order to assess whether or not results 
can be influenced by systematic errors and deviates from the truth, all important details regarding a specific type 
of bias need to be reported. As a consequence, we can not reliably estimate how valid the results of the included 
studies are. We nevertheless included the poorly reported papers in this review because papers that do not report 
essential details are not necessarily methodologically impaired50. Nevertheless, it is important to emphasize 
Therapy remyelination OPCs Oligodendrocytes
Tested in 
clinical trial
Anti-Lingo-1-antibodies Increase (6) Not tested Not significant (1) Yes (II)
Apotransferrin Not significant (1) Decrease (1) Increase (2) No
Benztropine Not significant (1) Not tested Increase (1) No
Dizocilipine (MK801, MNDA receptor antagonist) Decrease (1) Not significant (1) Not significant (1) No
Ebselen (glutaminase inhibitor) Increase (1) Not tested Not tested Yes (II)
Electro acupuncture Increase (1) Increase (1) Increase (1) Yes (II)
Electromagnetic field stimulation Increase (2) Not tested Not tested Yes (II)
Epimedium flavonoids (extract of epimedium sagittatum) Increase (1) Decrease (1) Not significant (1) No
Estrogen receptor agonist G1 Not significant (1) Not tested Increase (1) No
Glatiramer Acetate (mixture of synthetic polypeptides) Increase (2) Not significant (2) Not significant (1) Yes (IV)
Iloprost (prostaglandin I2) Not significant (2) Increase (1) Not tested No
Indazol chloride (Estrogen receptor agonist) Increase (1) Not tested Not significant (1) No
Lactacystin (Proteasome inhibitor) Not significant (1) Decrease (1) Not tested No
N6-cyclohexyladenosine (Adenosine A1-receptor agonist) Increase (1) Not tested Not tested No
Neurotrophin 3 Increase (1) Not tested Not significant (1) No
Ninjin’yoeito (extract from different medicinal herbs) Increase (1) Not tested Not tested No
Olesoxime (cholesterol-like compound) Not significant (3) Not significant (1) Increase (2) Yes (I)
Pigment epithelium-derived factor (PEDF) Not tested Increase (1) Increase (1) No
Plateled derived growth factor (PDGF) Increase (1) Increase (1) Not tested No
Progesterone Increase (3) Not significant (1) Increase (2) Yes (III)
Quetiapine (atypical antipsychotic) Increase (3) Not significant (1) Increase (2) Yes (II)
Sildenafil (phosphodiesterase inhibitor) Increase (1) Not tested Not tested No
Simvastatin (HMG-CoA reductase inhibitor) Decrease (2) Not significant (1) Not significant (1) Yes (IV)
siRNA against Nogo-receptor Increase (1) Not tested Not tested No
Sonic hedgehog Not tested Not tested Increase (1) No
Testosterone Increase (1) Increase (1) Increase (1) Yes (II)
Tocopherol derivate TFA-12 (Vitamin E derivate) Increase (1) Not significant (1) Increase (1) No
Trapidil (PDGF agonist) Decrease (1) Not tested Not tested No
Triiodothyronine Increase (4) Increase (1) Increase (4) Yes (I)
Valproic acid (antiepileptic) Decrease (1) Increase (1) Decrease (1) No
Vitamin E Increase (3) Not tested Not tested Yes (II)
Table 5. Summary of meta-analysis results for beneficial/harmful therapies on the outcomes remyelination, 
oligodendrocyte precursor cell (OPC) count, and oligodendrocyte count. The numers in brackets in the second 
to fourth columns indicate the number of comparisons for each outcome. The roman number in brackets in the 
last column indicates the latest phase of clinical trial the therapy has entered.
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that consistent reporting of essential details regarding experimental design for future animal experiments, as 
described for example in the ARRIVE guidelines51, is urgently needed.
Secondly, in this review we focused on models of toxic demyelination, namely anti-galactocerebroside anti-
bodies, cuprizone, ethidium bromide, and lysolecithin. These models are believed to be more suited to assess 
potential remyelinating interventions due to a clear temporal separation of de- and remyelination and only min-
imal overlying inflammatory processes11. This is in contrast to viral MS animal models or EAE, the most widely 
used MS animal model, being yet more suitable to study (neuro-)inflammatory processes of MS52. A recent 
meta-analysis revealed that Cyclosporin, Fingolimod, Glatiramer Acetate, Minocycline, and Vitamin D among 
others improved neuro-behavioral outcome in EAE21. Glatiramer Acetate also had a beneficial effect on remyeli-
nation in our meta-analysis. Fingolimod, on the other hand, did not significantly enhance remyelination in our 
Figure 10. Scatter plot of standardized mean differences (SMD) from the present meta-analysis of therapies 
which were assessed in at least two outcomes (remyelination, oligodendrocyte cell count (OL), oligodendrocyte 
precursor cell count (OPC)). Remyelination versus OL (A) shows a significant positive correlation (Pearson’s 
r = 0.51, two-tailed p < 0.02). Neither remyelination versus OPC (B) nor OPC versus OL (C) show a significant 
correlation.
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analysis. Both drugs are FDA-approved for relapsing MS. Interestingly, Methylprednisolone showed neither a 
beneficial effect on neurobehavioral recovery nor on remyelination in the meta-analysis even though being com-
monly used as treatment for acute MS relapses. This emphasizes that despite the usefulness of MS animal models 
in developing novel MS therapies, findings cannot be strictly translated to MS.
Thirdly, for many analyses the number of studies was low and the variation between the studies high. This 
influences the reliability of the conclusions drawn from this systematic review. For example, in this review we 
pooled the different toxic demyelination models as well as the different methods to assess the outcomes, neglect-
ing strengths and weaknesses of various models and outcomes individually. For example, the gold standard of 
assessing remyelination is the evidence of thinly myelinated axons in electron microscopy. Thus, the most com-
monly used readout in the included studies to assess remyelination was the evidence of thinly myelinated axons 
in electron microscopy (29%). Whereas methods demonstrating thinly myelinated axons are an acceptable com-
promise to show remyelination (e.g. semithin sections, MBP53, or sudan black54), other methods are less sensitive 
and/or specific. LFB was used by 19% of the studies to investigate remyelination upon therapy even though it 
does not reliably demonstrate single axon/myelin sheath resolution. For now, we have accounted for anticipated 
heterogeneity by using a random rather than fixed effects meta-analysis.
Furthermore, it is important to realize that no animal model is a perfect match to represent the full clinical 
situation. The results coming from animal studies are therefore always indirect55,56.
When the results of this review will be used to inform the clinical field, the applicability and feasibility of the 
promising therapeutic strategies mentioned in this paper need to be carefully assessed as well. In addition, poten-
tial adverse side effects of therapies in both animals and humans is another important determinant for clinical 
translation. Safety profile is completely neglected by our analysis (as it is in most pre-clinical studies, however) but 
needs to be included for clinical translation.
Phase Count Trial information NCT (if available)
1
4
Olesoxime Add-on therapy for Interferon β1 NCT01808885
Serum-derived human 
monoclonal IgM22 — NCT01803867
Thymosin beta4 — planned according to RegeneRX
Triiodothyronine For RRMS, SPMS, and PPMS NCT02506751, NCT02760056
2
10
Anti-Lingo-1 antibody Add-on therapy for Interferon β1 NCT01864148
Cyclosporin61
Electro-acupuncture62
Electromagnetic field 
stimulation63
Erythropoietin PPMS or SPMS NCT01144117
Melatonin RRMS NCT01279876
Quetiapine For RRMS and SPMS NCT02087631
Testosteron For male patients NCT00405353
Vitamin E Combined with Selenium NCT00010842
Ebselen Combined with Vitamin E NCT00010842
3
3
Laquinimod For RRMS NCT01047319
Minocycline For clinically isolated syndrome NCT00666887
Progesterone To prevent postpartum relapses NCT00127075
4
8
Fingolimod FDA-approved for RRMS
Fumaric acid ester FDA-approved for RRMS
Glatiramer acetate FDA-approved for RRMS
Methotrexat FDA-approved for RRMS
Methylprednisolone FDA-approved for RRMS
Omega-3 poly unsaturated fatty 
acid (PUFA) diet For RRMS NCT01842191
Simvastatin Add-on therapy for Interferon β1 (and phase 3 for SPMS) NCT00492765
Vitamin D Add-on therapy for Interferon β1 NCT01005095
Total 25 (30% of the 84 different therapies from our screening)
Table 6. Clinical trials for therapies potentially promoting remyelination with trial information and NCT 
(if available). Abbreviations: MS, multiple sclerosis; PP, primary progressive; SP, secondary progressive; RR, 
relapsing remitting.
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Lastly, we did not perform post-hoc power-calculations due to their limited validity. The sample sizes, how-
ever, were small in most of the included studies. Whereas we cannot draw direct conclusions on the power of 
the here included studies, it has been shown that the average statistical power of studies in neurosciences is very 
low57. With lower power, the likelihood that a statistically significant result reflects a true effect decreases58. This 
has important implications for successful clinical translation of pre-clinical evidence in animals because effects of 
a potential intervention might be overestimated in underpowered animal studies57.
Conclusions
We identified in this meta-analysis 16 potential therapies to improve remyelination in MS patients that have not 
yet been tested in clinical trials: Apotransferrin, Benztropine, Epimedium flavonoids, Estrogen receptor agonist 
G1, Iloprost, Indazol chloride, N6-cyclohexyladenosine, Neurotrophin 3, Ninjin’yoeito, Olesoxime, PEDF, PDGF, 
Sildenafil, siRNA against Nogo-receptor, Sonic hedgehog, and Tocopherol derivate TFA-12. However, before 
these therapies should be tested in clinical trials, the safety, applicability, and feasibility of the promising therapies 
need to be carefully assessed as well. The cross-species translation to humans in clinical trials so far was, however, 
less successful in some cases. Improving the reporting and possibly the methodological quality of animal studies 
can help to smoothen this important translation of remyelinating therapies to clinical use. This can also help to 
reduce animal numbers by making animal research more reliable.
Materials and Methods
This systematic review investigates the effects of remyelination promoting therapies in multiple sclerosis animal 
models. The inclusion criteria and method of analysis were specified in advance and documented in a protocol 
(Ineichen et al. (2017) and put online on the SYRCLE website in the section protocols (www.syrcle.nl).
search strategy and paper selection. A comprehensive search string to identify studies assessing poten-
tially remyelinating interventions in an animal model of toxic demyelination (Anti-galactocerebroside antibodies, 
ethidium bromide, cuprizone, and/or lysolecithin) was generated. The following data bases were searched for 
matches: EMBASE, go3R, Medline, Pubmed, Scopus, and Web of Sciences (last search 04th of July, 2016). See 
supplementary file for exact search strings (Supplementary Information). All animal species, publication dates, 
and languages were included to the data base search.
Studies were included in this systematic review when they met the following inclusion criteria: (1) the study 
was an original peer reviewed full paper that published unique data, (2) the study included an appropriate control 
group (vehicle only treatment), (3) an animal model of toxic demyelination (Anti-galactocerebroside antibodies, 
ethidium bromide, cuprizone, and/or lysolecithin) was used, (4) An outcome measure related to remyelination 
or (pre-)myelinating cell count was used.
Papers were screened for relevance by two independent reviewers (AG and BVI for anti-galactocerebroside 
antibodies, ethidium bromide, and cuprizone; GG and LB for lysolecithin). Reviews were excluded but retained 
as a source for potential studies and for discussion.
Data extraction. The following study characteristics were extracted from the full-texts: type of demyelina-
tion model, tested intervention, application regimen, species, strain, sex, and number of animals per group. As 
study outcomes measures, we extracted the mean and variance (Standard deviation (SD) or standard error of the 
mean (SEM)) of the outcome most closely related to remyelination. Since certain remyelination outcomes more 
reliably measure remyelination than others (e.g electron microscopy is more reliable than quantifying remyeli-
nation by measuring optical density of an LFB stained lesion), the following extraction priority was used for the 
remyelination outcomes: (1) Electron microscopy analysis of remyelination, (2) Toluidine blue/semithin section 
analysis of remyelination, (3) Analysis of other stainings that allow measurement of remyelination (i.e. dispro-
portionally thinly myelinated myelin sheets surrounding axons, e.g. MBP staining53, sudan black staining54), (4) 
Analysis of lesion volume/area in other stainings (e.g. MBP or LFB), (5) Analysis of lesion volume/area in MRI, 
and (6) Analysis of optical intensity in other stainings (e.g. MBP or LFB). Additionally, mean counts and variance 
(SD or SEM) of OPCs and/or oligodendrocytes were extracted if available. AG and BVI extracted the data for 
anti-galactocerebroside-antibodies, ethidium bromide, and cuprizone models; GG and LB extracted the data for 
all lysolecithin models). BVI checked if all data were extracted correctly. Disagreement between two extractors 
was solved by checking the data in the publications together. The interrater agreement was 60% for remyelination 
and oligodendrocytes, and 84% for OPCs.
In first priority, data was extracted from text or tables, in second priority from graphs using universal desktop 
ruler software (AVP Software Development, USA). In case of missing data, corresponding authors were contacted 
with maximally one email.
When the group size was reported as a range (e.g., 6–9), the mean number of animals was used in our analysis.
Quality assessment. To estimate risk of bias (RoB) of each study, we judged the study using the SYRCLE 
RoB-assessment tool, which is an adapted version of the Cochrane RoB tool20. Two independent reviewers 
assessed the risk of bias in each included paper (AG and BVI for anti-galactocerebroside antibodies, ethidium 
bromide, and cuprizone; GG and LB for lysolecithin). A ‘yes’ score indicates low risk of bias; a ‘no’ score indicates 
high risk of bias; and a ‘?’ score indicates unknown risk of bias.
To overcome the problem of judging too many items as “unclear risk of bias” because reporting of experimen-
tal details on animals, methods and materials is very poor, we added two items on reporting: reporting of any 
measure of randomization, reporting of any measure of blinding.
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Furthermore, we looked at 3 more items to measure overall quality of the included papers according to the 
consensus statement good laboratory practice in the modelling of stroke59: sample size calculations provided, 
reporting of animal welfare, and statement of a potential conflict of interest. For these three items, a ‘yes’ score 
indicates ‘reported’, and a ‘no’ score indicates ‘unreported’.
Meta-analysis. Data were analyzed using Comprehensive Meta-Analysis (CMA version2.0). Because in this 
Meta-analysis different studies used different scales to measure the same outcome, we calculated the hedges g 
standardized mean difference (SMD) instead of the raw mean difference (the mean of the experimental group 
minus the mean of the control group divided by the pooled SDs of the two groups).
When a control group served more than one experimental group, the number of observations in that control 
group was, for the purpose of the meta-analysis, divided by the number of experimental groups served, to make 
sure that the experiment does not receive too much weight in the meta analyses.
Individual effect sizes (in this case SMDs) were subsequently pooled to obtain an overall SMD and 95% con-
fidence interval. We used the random effects model [14], which takes into account the precision of individual 
studies and the variation between studies and weighs each study accordingly.
Sources for heterogeneity were explored with predefined subgroup analyses for intervention type, timing of 
the intervention (prophylactic or therapeutic) and type of MS model used (cuprizone, lysolecithin, ethidium 
bromide and anti-galactocerebroside antibodies).
We expected the variance to be comparable within the subgroups; therefore, we assumed a common 
among-study variance across subgroups. Statistical differences between subgroups were only assessed when sub-
groups contained at least 5 independent experiments per subgroup.
For those subgroup analyses, we adjusted our significance level according to the conservative Bonferroni 
method to account for multiple analyses (p* number of comparisons). However, differences between subgroups 
should be interpreted with caution and should only be used for constructing new hypotheses rather than for 
drawing final conclusions. No sub-subgroup analyses were calculated due to low number of experiments per 
therapeutic approach.
We used funnel plots, Egger regression and Trim and Fill analysis to search for evidence of publication bias. 
Because SMDs may cause funnelplot distortion we plotted the SMD against a sample size-based precision esti-
mate (1/√(n))60.
References
 1. Organization, W. H. Multiple Sclerosis International Federation. Atlas: Multiple Sclerosis Resources in the World 2008. World Health 
Organization, Geneva, Switzerland 13–17 (2008).
 2. Montalban, X. et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. The New England journal of medicine 
376, 209–220, https://doi.org/10.1056/NEJMoa1606468 (2017).
 3. Ineichen, B. V. et al. Nogo-A Antibodies for Progressive Multiple Sclerosis. CNS drugs 31, 187–198 (2017).
 4. Nave, K. A. Myelination and support of axonal integrity by glia. Nature 468, 244–252, https://doi.org/10.1038/nature09614 (2010).
 5. Sospedra, M. & Martin, R. Immunology of multiple sclerosis. Annual review of immunology 23, 683–747, https://doi.org/10.1146/
annurev.immunol.23.021704.115707 (2005).
 6. Gold, R., Linington, C. & Lassmann, H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years 
of merits and culprits in experimental autoimmune encephalomyelitis research. Brain: a journal of neurology 129, 1953–1971, 
https://doi.org/10.1093/brain/awl075 (2006).
 7. Mecha, M., Carrillo-Salinas, F. J., Mestre, L., Feliu, A. & Guaza, C. Viral models of multiple sclerosis: neurodegeneration and 
demyelination in mice infected with Theiler’s virus. Progress in neurobiology 101-102, 46–64, https://doi.org/10.1016/j.
pneurobio.2012.11.003 (2013).
 8. Kipp, M., Clarner, T., Dang, J., Copray, S. & Beyer, C. The cuprizone animal model: new insights into an old story. Acta 
neuropathologica 118, 723–736, https://doi.org/10.1007/s00401-009-0591-3 (2009).
 9. Woodruff, R. H. & Franklin, R. J. Demyelination and remyelination of the caudal cerebellar peduncle of adult rats following 
stereotaxic injections of lysolecithin, ethidium bromide, and complement/anti-galactocerebroside: a comparative study. Glia 25, 
216–228 (1999).
 10. Blakemore, W. F. & Franklin, R. J. Remyelination in experimental models of toxin-induced demyelination. Current topics in 
microbiology and immunology 318, 193–212 (2008).
 11. Dubois-Dalcq, M., Ffrench-Constant, C. & Franklin, R. J. Enhancing central nervous system remyelination in multiple sclerosis. 
Neuron 48, 9–12, https://doi.org/10.1016/j.neuron.2005.09.004 (2005).
 12. Zendedel, A., Beyer, C. & Kipp, M. Cuprizone-induced demyelination as a tool to study remyelination and axonal protection. J Mol 
Neurosci 51, 567–572, https://doi.org/10.1007/s12031-013-0026-4 (2013).
 13. Denic, A. et al. The relevance of animal models in multiple sclerosis research. Pathophysiology: the official journal of the International 
Society for Pathophysiology/ISP 18, 21–29, https://doi.org/10.1016/j.pathophys.2010.04.004 (2011).
 14. Moher, D. et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality 
of Reporting of Meta-analyses. Lancet (London, England) 354, 1896–1900 (1999).
 15. Hall, S. M. & Gregson, N. A. The in vivo and ultrastructural effects of injection of lysophosphatidyl choline into myelinated 
peripheral nerve fibres of the adult mouse. Journal of cell science 9, 769–789 (1971).
 16. Blakemore, W. F. Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone 
intoxication in mice. Journal of neurocytology 1, 413–426 (1972).
 17. Yajima, K. & Suzuki, K. Ultrastructural changes of oligodendroglia and myelin sheaths induced by ethidium bromide. 
Neuropathology and applied neurobiology 5, 49–62 (1979).
 18. Saida, K., Saida, T., Brown, M. J. & Silberberg, D. H. In vivo demyelination induced by intraneural injection of anti-galactocerebroside 
serum: a morphologic study. The American journal of pathology 95, 99–116 (1979).
 19. McKay, J. S., Blakemore, W. F. & Franklin, R. J. The effects of the growth factor-antagonist, trapidil, on remyelination in the CNS. 
Neuropathology and applied neurobiology 23, 50–58 (1997).
 20. Hooijmans, C. R. et al. SYRCLE’s risk of bias tool for animal studies. BMC medical research methodology 14, 43, https://doi.
org/10.1186/1471-2288-14-43 (2014).
 21. Vesterinen, H. M. et al. Improving the translational hit of experimental treatments in multiple sclerosis. Multiple sclerosis 
(Houndmills, Basingstoke, England) 16, 1044–1055, https://doi.org/10.1177/1352458510379612 (2010).
www.nature.com/scientificreports/
1 6Scientific RepoRts |           (2019) 9:822  | https://doi.org/10.1038/s41598-018-35734-4
 22. Sena, E., Wheble, P., Sandercock, P. & Macleod, M. Systematic review and meta-analysis of the efficacy of tirilazad in experimental 
stroke. Stroke; a journal of cerebral circulation 38, 388–394, https://doi.org/10.1161/01.STR.0000254462.75851.22 (2007).
 23. Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Statistics in medicine 21, 1539–1558, https://doi.
org/10.1002/sim.1186 (2002).
 24. Ciurleo, R., Bramanti, P. & Marino, S. Role of statins in the treatment of multiple sclerosis. Pharmacological research 87, 133–143, 
https://doi.org/10.1016/j.phrs.2014.03.004 (2014).
 25. Chataway, J. et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-
STAT): a randomised, placebo-controlled, phase 2 trial. Lancet (London, England) 383, 2213–2221, https://doi.org/10.1016/s0140-
6736(13)62242-4 (2014).
 26. Chan, D. et al. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in 
secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. The Lancet. 
Neurology 16, 591–600, https://doi.org/10.1016/s1474-4422(17)30113-8 (2017).
 27. Sorensen, P. S. et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN 
study): a placebo-controlled randomised phase 4 trial. The Lancet. Neurology 10, 691–701, https://doi.org/10.1016/s1474-
4422(11)70144-2 (2011).
 28. Miron, V. E. et al. Simvastatin regulates oligodendroglial process dynamics and survival. Glia 55, 130–143, https://doi.org/10.1002/
glia.20441 (2007).
 29. Miron, V. E. et al. Statin therapy inhibits remyelination in the central nervous system. The American journal of pathology 174, 
1880–1890, https://doi.org/10.2353/ajpath.2009.080947 (2009).
 30. Maier, O., De Jonge, J., Nomden, A., Hoekstra, D. & Baron, W. Lovastatin induces the formation of abnormal myelin-like membrane 
sheets in primary oligodendrocytes. Glia 57, 402–413, https://doi.org/10.1002/glia.20769 (2009).
 31. Shen, S. et al. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nature 
neuroscience 11, 1024–1034, https://doi.org/10.1038/nn.2172 (2008).
 32. Azuchi, Y. et al. Valproic acid and ASK1 deficiency ameliorate optic neuritis and neurodegeneration in an animal model of multiple 
sclerosis. Neurosci Lett 639, 82–87, https://doi.org/10.1016/j.neulet.2016.12.057 (2017).
 33. Castelo-Branco, G. et al. Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune 
encephalomyelitis and prevents brain pathology in DA rats. Neurobiology of disease 71, 220–233, https://doi.org/10.1016/j.
nbd.2014.08.019 (2014).
 34. Nielsen, N. M. et al. The use of valproic acid and multiple sclerosis. Pharmacoepidemiology and drug safety 24, 262–268, https://doi.
org/10.1002/pds.3692 (2015).
 35. Chari, D. M., Zhao, C., Kotter, M. R., Blakemore, W. F. & Franklin, R. J. Corticosteroids delay remyelination of experimental 
demyelination in the rodent central nervous system. Journal of neuroscience research 83, 594–605, https://doi.org/10.1002/jnr.20763 
(2006).
 36. Woodruff, R. H., Fruttiger, M., Richardson, W. D. & Franklin, R. J. Platelet-derived growth factor regulates oligodendrocyte 
progenitor numbers in adult CNS and their response following CNS demyelination. Molecular and cellular neurosciences 25, 
252–262, https://doi.org/10.1016/j.mcn.2003.10.014 (2004).
 37. Reynolds, R. et al. The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. Journal of 
neurocytology 31, 523–536 (2002).
 38. Back, S. A. et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nature 
medicine 11, 966 (2005).
 39. Wolswijk, G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain: a journal of neurology 125, 
338–349 (2002).
 40. Chang, A., Nishiyama, A., Peterson, J., Prineas, J. & Trapp, B. D. NG2-positive oligodendrocyte progenitor cells in adult human brain 
and multiple sclerosis lesions. The Journal of neuroscience: the official journal of the Society for Neuroscience 20, 6404–6412 (2000).
 41. Chang, A., Tourtellotte, W. W., Rudick, R. & Trapp, B. D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. 
The New England journal of medicine 346, 165–173, https://doi.org/10.1056/NEJMoa010994 (2002).
 42. Scolding, N. et al. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. 
Brain: a journal of neurology 121(Pt 12), 2221–2228 (1998).
 43. Moll, N. M. et al. SOX17 is expressed in regenerating oligodendrocytes in experimental models of demyelination and in multiple 
sclerosis. Glia 61, 1659–1672, https://doi.org/10.1002/glia.22547 (2013).
 44. Maire, C. L., Wegener, A., Kerninon, C. & Nait Oumesmar, B. Gain-of-function of Olig transcription factors enhances 
oligodendrogenesis and myelination. Stem cells (Dayton, Ohio) 28, 1611–1622, https://doi.org/10.1002/stem.480 (2010).
 45. Franklin, R. J. M. & Ffrench-Constant, C. Regenerating CNS myelin - from mechanisms to experimental medicines. Nature reviews. 
Neuroscience 18, 753–769, https://doi.org/10.1038/nrn.2017.136 (2017).
 46. Bondan, E. F., Martins Mde, F., Branco, A. M. & Lallo, M. A. Semi-quantitative analysis of the effects of cyclosporine on 
remyelination following gliotoxic injection in the brainstem. Arquivos de neuro-psiquiatria 69, 377–383 (2011).
 47. Rudge, P. Cyclosporine and multiple sclerosis: the cons. Neurology 38, 29–30 (1988).
 48. Robinson, A. P., Harp, C. T., Noronha, A. & Miller, S. D. The experimental autoimmune encephalomyelitis (EAE) model ofMS: 
utility for understanding disease pathophysiology and treatment. Handbook of clinical neurology 122, 173–189, https://doi.
org/10.1016/b978-0-444-52001-2.00008-x (2014).
 49. Hooijmans, C. R., Geessink, F. J., Ritskes-Hoitinga, M. & Scheffer, G. J. A systematic review and meta-analysis of the ability of 
analgesic drugs to reduce metastasis in experimental cancer models. Pain 156, 1835–1844, https://doi.org/10.1097/j.
pain.0000000000000296 (2015).
 50. Green, S. & Higgins, J. (Version, 2005).
 51. Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE 
guidelines for reporting animal research. PLoS biology 8, e1000412, https://doi.org/10.1371/journal.pbio.1000412 (2010).
 52. Lassmann, H. & Bradl, M. Multiple sclerosis: experimental models and reality. Acta neuropathologica, https://doi.org/10.1007/
s00401-016-1631-4 (2016).
 53. Watanabe, M., Toyama, Y. & Nishiyama, A. Differentiation of proliferated NG2-positive glial progenitor cells in a remyelinating 
lesion. Journal of neuroscience research 69, 826–836, https://doi.org/10.1002/jnr.10338 (2002).
 54. Ineichen, B. V. et al. Sudan black: a fast, easy, and non-toxic method to assess myelin repair in demyelinating diseases. Neuropathology 
and applied neurobiology, https://doi.org/10.1111/nan.12373 (2016).
 55. Hooijmans, C. R. et al. Facilitating healthcare decisions by assessing the certainty in the evidence from preclinical animal studies. 
PloS one 13, e0187271, https://doi.org/10.1371/journal.pone.0187271 (2018).
 56. Iqbal, S. A., Wallach, J. D., Khoury, M. J., Schully, S. D. & Ioannidis, J. P. Reproducible Research Practices and Transparency across 
the Biomedical Literature. PLoS biology 14, e1002333, https://doi.org/10.1371/journal.pbio.1002333 (2016).
 57. Button, K. S. et al. Power failure: why small sample size undermines the reliability of neuroscience. Nature reviews. Neuroscience 14, 
365–376, https://doi.org/10.1038/nrn3475 (2013).
 58. Marino, M. J. How Often Should We Expect to be Wrong? Statistical Power, P Values, and the Expected Prevalence of False 
Discoveries. Biochemical pharmacology, https://doi.org/10.1016/j.bcp.2017.12.011 (2017).
www.nature.com/scientificreports/
17Scientific RepoRts |           (2019) 9:822  | https://doi.org/10.1038/s41598-018-35734-4
 59. Macleod, M. R. et al. Reprint: Good laboratory practice: preventing introduction of bias at the bench. Journal of cerebral blood flow 
and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 29, 221–223, https://doi.
org/10.1038/jcbfm.2008.101 (2009).
 60. Zwetsloot, P. P. et al. Standardized mean differences cause funnel plot distortion in publication bias assessments. eLife 6, https://doi.
org/10.7554/eLife.24260 (2017).
 61. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled 
clinical trial. The Multiple Sclerosis Study Group. Annals of neurology 27 591–605, https://doi.org/10.1002/ana.410270603 (1990).
 62. Quispe-Cabanillas, J. G. et al. Impact of electroacupuncture on quality of life for patients with Relapsing-Remitting Multiple 
Sclerosis under treatment with immunomodulators: a randomized study. BMC complementary and alternative medicine 12, 209, 
https://doi.org/10.1186/1472-6882-12-209 (2012).
 63. Lappin, M. S., Lawrie, F. W., Richards, T. L. & Kramer, E. D. Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue 
and quality of life: a double-blind, placebo controlled trial. Alternative therapies in health and medicine 9, 38–48 (2003).
Acknowledgements
This work was supported by grants of the Swiss National Science Foundation (No. 323530_151488, to BVI); the 
Swiss MS Society; the Hartmann‐Müller Foundation, Zurich; and the Desirée‐and‐Niels‐Yde Foundation (to 
BVI). We cordially thank Prof. Malcolm MacLeod (University of Edinburgh) for critical input on the manuscript. 
We thank Martina Gosteli (University of Zurich) for help with the literature search. We also thank A. Stanchinsky 
and A. Scriabin for help with data extraction.
Author Contributions
B.V.I. and M.H. designed the project; B.V.I., C.R.H. and F.A.F.S. wrote the manuscript and provided figures; M.H., 
B.V.I., A.G., N.G., L.B. and G.G. did the abstract sorting and full-text extraction; C.R.H. performed the meta-
analysis; C.R.H., F.A.F.S., R.d.V., M.P.S. and T.J. gave critical input to the conceptual development of the study and 
the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-35734-4.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
